טוען...
Extreme Prostate‐Specific Antigen Response to Infusional 5‐Flourouracil in Castrate‐Resistant Prostate Cancer
Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous‐infusion 5‐fluorouracil (5‐FU) at a dose of 200 mg/m(2) in a patient with rapidly progressive, heavily pretreated,...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AlphaMed Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905692/ https://ncbi.nlm.nih.gov/pubmed/29259071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0450 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|